Forecast

The analysts' average price target is €47.70 (+47.68%). The median is €45.99 (+42.38%).

Buy	11
Hold	1
Sell	0

News Go to news feed

Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data

Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » More on de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug

Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » More on de.investing.com
Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks

Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Pharvaris Aktie has already paid €0.10 in dividends. The last payout was in July 2022.

Financials

In the last quarter, Pharvaris Aktie had revenue of €0 and net profit of -€47.84M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-47.84M	5.19%
EBITDA	-50.66M	12.15%

Fundamentals

Metric	Value
Market capitalization	€2.27B
Number of shares	69.88M
52-week high/low	€37.18 - €17.75
Dividends	No
Beta	-2.32
P/E ratio	-12.05
PEG ratio	-0.94
P/B ratio	7.36
P/S ratio	0.00

Company profile

Pharvaris N.V., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung von Therapien für seltene Krankheiten. Das Unternehmen entwickelt PHA121, einen niedermolekularen Bradykinin-B2-Rezeptor-Antagonisten, der sich in einer klinischen Phase-II-Studie zur Behandlung des hereditären Angioödems (HAE) befindet. Darüber hinaus entwickelt das Unternehmen PHVS416, eine Weichkapsel, die bei Bedarf schnell freigesetzt wird, für Patienten, die unter akuten HAE-Attacken leiden, und befindet sich in einer klinischen Phase-2-Studie; und PHVS719, eine prophylaktische Tablette mit verlängerter Wirkstofffreisetzung für HAE-Patienten, die sich in einer klinischen Phase-1-Studie befindet. Das Unternehmen ist in den Niederlanden, der Schweiz und den Vereinigten Staaten tätig. Das Unternehmen wurde 2015 gegründet und hat seinen Sitz in Leiden in den Niederlanden.